Cadence Pharmaceuticals Inc. Reaches New 12-Month High at $10.16 (CADX)
Cadence Pharmaceuticals (NASDAQ:CADX)’s share price reached a new 52-week high during trading on Thursday, American Banking News reports. The stock traded as high as $10.16 and last traded at $10.08, with a volume of 724,808 shares traded. The stock had previously closed at $9.60.
Several analysts have recently commented on the stock. Analysts at Guggenheim raised their price target on shares of Cadence Pharmaceuticals from $9.00 to $15.00 in a research note to investors on Tuesday, December 3rd. They now have a “buy” rating on the stock. Analysts at Pacific Crest upgraded shares of Cadence Pharmaceuticals to an “outperform” rating in a research note to investors on Tuesday, November 26th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $9.19.
Cadence Pharmaceuticals has a one year low of $4.45 and a one year high of $10.09. The stock has a 50-day moving average of $9.1 and a 200-day moving average of $6.88. The company’s market cap is $885.0 million.
Cadence Pharmaceuticals, Inc operates as a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics utilized primarily in the hospital setting.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.